Obesity biotech Kailera’s record-breaking IPO
Pharmaphorum
When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled.
S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced Setting
OncLive Podcast
In this podcast, experts Barbara Burtness, MD; and Quynh-Thu Le, MD, FACR, FASTRO; discuss recent and ongoing trials and key updates in the management of locally advanced head and neck cancer.
UPDATE: Kailera breaks biotech IPO record with $625M debut
BioSpace
Obesity-focused Kailera Therapeutics debuted on the Nasdaq Friday after raising a record $625 million, beating Moderna’s $600 million from 2018.
RFK Jr. defends Makary, claims pharma ‘owns’ Congress and media
BioSpace
The pharma industry “own Congress, they own the media,” Health Secretary Robert F.
OpenAI introduces GPT-Rosalind, its drug discovery AI
Pharmaphorum
In this week’s second AI model launch for life sciences research, OpenAI has introduced GPT-Rosalind, named after UK scientist Rosalind Franklin.
Novo may have muscle advantage over Lilly in weight-loss race: preprint
BioSpace
More patients on Eli Lilly’s tirzepatide lost over 5% of their lean mass versus those on Novo Nordisk’s semaglutide, according to a study that has yet to be peer reviewed.
Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA
BioSpace
After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency’s lack
Multiple myeloma drug Blenrep backed for wider NHS use
Pharmaphorum
The revitalisation of GSK’s Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple myeloma drug more widely.
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Pharmaceutical Business Review
The agreement involves Daiichi Sankyo Research Institute Boston and aims to assess the use of Interna’s MNM technology as a delivery enhancer for therapeutic modalities.
Aligos and Xiamen Amoytop sign deal for HBV therapy
Pharmaceutical Technology
Aligos Therapeutics and Xiamen Amoytop Biotech are to develop and commercialise pevifoscorvir sodium in Greater China for chronic HBV infection.
The innovators working to make in vivo cell therapy a reality
Pharmaceutical Technology
As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.
Trump names Erica Schwartz to fill leadership void at CDC
Pharmaphorum
Former Deputy Surgeon General Erica Schwartz could end months at the CDC without Senate-confirmed leadership if she becomes Director.
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Pharmaceutical Technology
Daiichi Sankyo has partnered with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology.
Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director
BioPharma Dive
If confirmed by the Senate, Schwartz could finally fill a void for an agency that s cycled through multiple leaders over the last year.
FDA moves toward easing restrictions on certain peptides
BioPharma Dive
The agency s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F.
Lilly’s new obesity pill passes heart safety test in diabetes
BioPharma Dive
The findings, which come amid FDA scrutiny of Foundayo s safety, will enable Lilly to seek a new clearance in diabetes.
Lilly debuts more Foundayo data as FDA requests post-marketing trials
Pharmaceutical Technology
The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial.
Roche to start new Elevidys study following setback in Europe
BioPharma Dive
The Swiss drugmaker, which owns rights to the Duchenne gene therapy outside the U.S., hopes the trial will yield additional approvals in Europe and elsewhere.
Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns
BioSpace
Right after the FDA flagged safety concerns for Eli Lilly’s newly approved obesity pill, the pharma posted diabetes data demonstrating a clean safety profile and revealed plans to seek approval in the
Obesity’s explosive growth continues as Q1 deals exceed total 2025 value
BioSpace
Commitments in obesity- and diabetes-focused deals reached $22 billion in the first quarter of 2026–already eclipsing last year’s total of $20.3 billion, according to a new J.P.